Lexeo Therapeutics provided encouraging interim data from the HEROIC-PKP2 Phase I/II clinical trial of LX2020 for PKP2-Associated Arrhythmogenic Cardiomyopathy.
LX2020 demonstrated favorable safety profile, robust transduction, increased PKP2 protein expression, and improvement in arrhythmia burden across participants.
Preliminary results indicate potential therapeutic benefits in addressing the underlying cause of cardiac dysfunction in PKP2-ACM patients.
Safety Profile
LX2020 was generally well tolerated with no significant complement activation; observed elevations in liver function tests were successfully managed per trial protocol.
PKP2 Protein Expression
Mean increase of 93% in low-dose and 162% in high-dose cohorts; significant transduction and protein expression seen via biopsies.
Clinical Improvement
Reduction or stabilization of non-sustained ventricular tachycardia and premature ventricular contractions; positive patient-reported outcomes and stable clinical measures.
- The interim data showcases promising trends in LX2020's efficacy and safety for treating PKP2-Associated Arrhythmogenic Cardiomyopathy.
- Participants demonstrated improved PKP2 protein expression and reduction in arrhythmia burden with dose-dependent responses, implying potential therapeutic value in cardiac dysfunction.
The positive interim data on LX2020 from the HEROIC-PKP2 trial signifies a significant step towards developing novel treatments for cardiovascular diseases like PKP2-Associated Arrhythmogenic Cardiomyopathy.